

## Health Economic Perspectives in Fibromyalgia: Focus on Pregabalin

This supplement to *The American Journal of Managed Care* discusses current evidence and strategies to improve clinical and economic outcomes associated with fibromyalgia treatment.

### ■ Faculty

#### **Jose Alvir, DrPH**

Senior Director  
Pfizer, Inc.  
New York, NY

#### **Lesley Arnold, MD**

Professor of Psychiatry  
University of Cincinnati College  
of Medicine  
Cincinnati, OH

#### **Gary Bazalo, MS, MBA**

Partner  
Managed Solutions, LLC  
Conifer, CO

#### **Ariel Berger, MPH**

Senior Analyst  
Policy Analysis Inc  
Brookline, MA

#### **William J. Cardarelli, PharmD**

Director of Pharmacy  
Harvard Vanguard Medical Associates  
Watertown, MA

#### **Arthi Chandran, MPH**

Associate Director  
Market Access-Global  
Health Economics and Outcomes  
Research  
Pfizer, Inc.  
New York, NY

#### **Daniel Clauw, MD**

Professor and Director  
Chronic Pain and Fatigue  
Research Center  
Department of Anesthesiology  
University of Michigan  
Ann Arbor, MI

#### **Michael Deminski, MS, RPh**

Senior Director, Medical Affairs  
Pfizer, Inc.  
New York, NY

#### **Ellen M. Dukes, PhD**

Senior Director  
Pfizer, Inc.  
New York, NY

#### **John Edelsberg, MD, MPH**

Medical Director  
Policy Analysis Inc  
Brookline, MA

#### **Mugdha Gore, PhD, BPharm**

Principal Consultant  
Avalon Health Solutions, Inc.  
Philadelphia, PA

#### **John Hanna, MBA**

Director, Health Services Research  
Humana Inc  
Health Services Research Center  
Miami, FL

#### **Ashish V. Joshi, PhD**

Associate Director  
Pfizer, Inc.  
New York, NY

#### **Hua Li, MD, PhD**

Biostatistician (Scientist)  
Humana Inc  
Miami, FL

#### **Philip Mease, MD**

Seattle Rheumatology Associates  
Director, Division of Rheumatology  
Research, Swedish Medical Center  
Clinical Professor, University of  
Washington School of Medicine  
Seattle, WA

#### **Gerry Oster, PhD**

Vice President  
Policy Analysis Inc  
Brookline, MA

#### **Ana Palacio, MD, MPH**

Assistant Professor  
Department of Medicine  
University of Miami  
Miami, FL

#### **Alesia Sadosky, PhD, MPH, MBA**

Director  
Pfizer, Inc.  
New York, NY

#### **Robert Sanchez, RPh, MS, PhDc**

Director, US Health Economics  
and Outcomes Research  
Pfizer, Inc.  
New York, NY

#### **Stuart Silverman, MD**

Clinical Professor of Medicine  
and Rheumatology  
UCLA/Cedars-Sinai Medical Center  
and OMC Clinical Research Center  
Los Angeles, CA

#### **Claudia L. Uribe, MD, MHA**

Manager, Health Services Research  
Humana Inc  
Miami, FL

#### **Richard C. Weiss, MS**

Partner  
Managed Solutions, LLC  
Mt. Freedom, NJ

#### **Gergana Zlateva, PhD**

Senior Director  
Global Market Access Lead, Lyrica  
Primary Care Business Unit  
Pfizer, Inc.  
New York, NY

## ■ Faculty Disclosures

These participants report relationships with the following organizations:

### **Jose Alvir, DrPH**

*Employee/stockholder:* Pfizer, Inc.

### **Lesley Arnold, MD**

*Consultant:* Allergan, AstraZeneca, Boehringer Ingelheim, Cypress Bioscience, Forest, Lilly, Pfizer, Inc., sanofi-aventis, Takeda, Theravance, UCB, Wyeth Pharmaceuticals

*Grant/research support:* Allergan, Boehringer Ingelheim, Cypress Bioscience, Forest, Lilly, Pfizer, Inc., Wyeth Pharmaceuticals

*Speakers' bureau:* Forest

### **Gary Bazalo, MS, MBA**

Receipt of payment for the conduct of the study and article development

### **Ariel Berger, MPH**

Employee of Policy Analysis Inc, which received financial support from Pfizer, Inc. for the conduct of this analysis and article development

### **Arthi Chandran, MPH**

*Employee/stockholder:* Pfizer, Inc.

### **Daniel Clauw, MD**

*Consultant:* AstraZeneca, Cypress Bioscience, Forest, Lilly, Pfizer, Inc., Pierre Fabre, UCB

*Grant/research support:* Forest, Pfizer, Inc.

### **Michael Deminski, MS, RPh**

*Employee/stockholder:* Pfizer, Inc.

### **Ellen M. Dukes, PhD**

*Employee/stockholder:* Pfizer, Inc.

### **John Edelsberg, MD, MPH**

Employee of Policy Analysis Inc, which received financial support from Pfizer, Inc. for the conduct of this analysis and article development

### **Mugdha Gore, PhD, BPharm**

Employee of Policy Analysis Inc, which received financial support from Pfizer, Inc. for the conduct of this analysis and article development

*Stockholder:* Pfizer, Inc.

### **John Hanna, MBA**

Consultant to Pfizer, Inc. during the conduct of this study and article development

### **Ashish V. Joshi, PhD**

*Employee/stockholder:* Pfizer, Inc.

### **Hua Li, MD, PhD**

Consultant to Pfizer, Inc. during the conduct of this study and article development

### **Philip Mease, MD**

*Consultant/grant recipient:* Allergan, Boehringer Ingelheim, Cypress Bioscience, Forest, Fralex, Lilly, Pfizer, Inc.

*Honoraria/speakers' bureau:* Cypress Bioscience, Forest, Lilly, Pfizer, Inc.

### **Gerry Oster, PhD**

Employee of Policy Analysis Inc, which received financial support from Pfizer, Inc. for the conduct of this analysis and article development

### **Ana Palacio, MD, MPH**

Consultant to Pfizer, Inc. during the conduct of this study and article development

### **Alesia Sadosky, PhD, MPH, MBA**

*Employee/stockholder:* Pfizer, Inc.

### **Robert Sanchez, RPh, MS**

*Employee/stockholder:* Pfizer, Inc.

### **Stuart Silverman, MD**

*Consultant/advisory board member:* Lilly, Pfizer, Inc.

*Grants:* Lilly, Pfizer, Inc.

*Lecture fees:* Lilly, Pfizer, Inc.

### **Claudia L. Uribe, MD, MHA**

Consultant to Pfizer, Inc. during the conduct of this study and article development

### **Richard C. Weiss, MS**

Receipt of payment for the conduct of the study and article development

### **Gergana Zlateva, PhD**

*Employee/stockholder:* Pfizer, Inc.

**William J. Cardarelli, PharmD**, has nothing to disclose relative to the topic of this supplement.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

---

## *Health Economic Perspectives in Fibromyalgia: Focus on Pregabalin®*

This supplement was funded by **Pfizer, Inc.**



The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.